First-In-Human Studies – An Examination of the Evolving Regulatory and Clinical Practices

Clinical Trials, Drug Discovery and Development, Drug Safety, Life Sciences, Pharmaceutical, Pharmaceutical Regulation ,
  • November 09, 2017

In this webinar, Syneos Health experts will discuss the evolving regulatory and clinical requirements to ensure safety and compliance when conducting First-in-Human studies.

First-in-human studies are a key milestone in drug development. In such studies, a drug already tested in a preclinical setting (in vitro, animals) is tested in humans for the first time. Study participants, who are often healthy volunteers, face an element of risk as the ability to predict the effects in humans is limited. In recent history, albeit in rare cases, study subjects have experienced serious harm in such trials. Regulatory guidelines have evolved following such events to ensure the safety and well-being of study subjects. Most recently in 2017, the European Medicines Agency (EMA) has revised its guidance on first-in-human trials. The revised guidance includes additional strategies to mitigate and manage risks for study subjects, including guidance for the calculation of the starting dose, rules for subsequent dose escalation and the criteria for establishing the maximum dose. The guidance also provides criteria to stop a study, review emerging data and handling of adverse events in relation to the study stopping rules.

Over recent years, first-in-human studies have become increasingly complex, focusing on multiple parts such as single-dose ascension, multiple-dose ascension, food interactions, different age groups or gender, proof of concept, or relative bioavailability of different formulations. While most first-in-human studies are conducted in healthy volunteers, other populations such as patients may need to be considered. As such, data generated during the course of the trial should be carefully reviewed and used to inform the decision to initiate a subsequent study part or to inform the selection of the doses to be evaluated.

This session will discuss the evolving requirements for conducting first-in-human studies and will focus on the key regulatory and clinical considerations in ensuring subject safety.

Speakers

John Oldenhof, PhD, Executive Director, Clinical Pharmacology, Early Phase, Syneos Health

Dr. John Oldenhof is Executive Director, Clinical Pharmacology at Syneos Health – Toronto, where he is responsible for the oversight of the Pharmacokinetic/Pharmacometric, Pharmacy, Compliance and Clinical Documentation teams. Dr. Oldenhof obtained his MSc and PhD in pharmacology from the University of Toronto in the areas of behavioral pharmacology and molecular neuropharmacology. Prior to joining Syneos Health in 2003, Dr. Oldenhof worked in the biotechnology sector. In this role, he was involved in the design and analysis of phase II and III studies and was responsible for the management and scientific oversight of non-clinical research programs at the Virginia Commonwealth University and the University of Western Ontario. At Syneos Health, Dr. Oldenhof has been involved in more than 300 Phase I clinical studies, including numerous first-in-man (FIM), single ascending dose (SAD) and multiple ascending dose (MAD). His experience is across a wide range of disease conditions with a variety of therapeutic strategies. He has more than 30 published research papers and conference abstracts.

Dr Richard Larouche Vice-President, Medical Affairs, Syneos Health

Dr. Larouche oversees the medical team in the Quebec, Canada unit and is the leading investigator in various early phase clinical trials in healthy volunteers and patients such as: first in human, SAD-MAD, drug-drug interaction, TQT, renal impaired, insulin clamp, PK-PD, and phase IIa. He has been involved in design and conduct of all innovator compound studies and biologics/biosimilars studies performed at Syneos Health for the last 16 years and he continues to work as a family physician in a community medical clinic.

Clark Williard, Executive Director, Bioanalysis, Early Stage Bioanalytical Labs, Syneos Health

Mr. Williard has more than 23 years of experience in the mass spectrometry bioanalysis field of research supporting the pharmaceutical industry. In 1994, Mr. Williard joined Taylor Technology, Inc., a start-up lab of 7 employees, focusing efforts in methods development and validation utilizing LC-MS/MS and GC-MS/MS techniques. Mr. Williard’s other interests included the development and deployment of Taylor Technology’s laboratory automation program.

At Syneos Health, Mr. Williard has held such laboratory positions as Senior Scientist and Research Scientist. He has functioned as bioanalytical Principal Investigator in regulated studies for 16 years. As Executive Director, Mr. Williard has overseen daily operations of the company’s bioanalytical mass spectrometry-based laboratories in Princeton, New Jersey and Quebec City, Canada consisting of 240+ highly skilled professionals. His responsibilities include financial performance, resource allocation, and new business development. He functions as GLP Manager and Site Head of the laboratories.

Mr. Williard holds a bachelor’s degree from Penn State University. He has authored various articles in peer-reviewed journals and book chapter contributions on bioanalysis supporting the oncology, biomarker, and medical device fields of research.

Who Should Attend?

Senior professionals from pharmaceutical and biotechnology companies working in early phase drug development, including the areas of:

  • Preclinical Development
  • Toxicology
  • Clinical Pharmacology
  • Toxicology
  • Clinical Operations
  • Data Management
  • Regulatory Affairs

What You Will Learn

  • Learn about the updated EMA guidelines on first-in-human studies and how they may impact your clinical trials
  • Discover strategies to optimize data review for safe dose escalation
  • Understand best practices in dose selection and risk mitigation

Xtalks Partners

Syneos Health

Syneos Health (Nasdaq:SYNH*) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com.

* We expect Syneos Health common shares to trade on the Nasdaq Global Select Market under the new name and new ticker symbol “SYNH” by January 9, 2018. Until then, Syneos Health will continue to be listed under INC Research Holdings, Inc. and the symbol “INCR.”

Related Webinars

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account